BeOne Medicines Balance Sheet Health
Financial Health criteria checks 4/6
BeOne Medicines has a total shareholder equity of $3.5B and total debt of $923.6M, which brings its debt-to-equity ratio to 26.4%. Its total assets and total liabilities are $5.8B and $2.3B respectively.
Key information
26.39%
Debt to equity ratio
US$923.63m
Debt
| Interest coverage ratio | n/a |
| Cash | US$2.52b |
| Equity | US$3.50b |
| Total liabilities | US$2.34b |
| Total assets | US$5.84b |
Recent financial health updates
Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?
Apr 23
Is BeiGene (NASDAQ:ONC) A Risky Investment?
Jan 14Recent updates
BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
Jun 04Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
May 15
US Facility And Phase III Trials Will Expand Markets
Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?
Apr 23BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Feb 28BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Feb 06Is BeiGene (NASDAQ:ONC) A Risky Investment?
Jan 14BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
Dec 01BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion
Nov 06BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat
Aug 22Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08Financial Position Analysis
Short Term Liabilities: ONC's short term assets ($3.9B) exceed its short term liabilities ($2.0B).
Long Term Liabilities: ONC's short term assets ($3.9B) exceed its long term liabilities ($358.3M).
Debt to Equity History and Analysis
Debt Level: ONC has more cash than its total debt.
Reducing Debt: ONC's debt to equity ratio has increased from 8.9% to 26.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ONC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ONC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/13 19:40 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeOne Medicines Ltd. is covered by 63 analysts. 34 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |